Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Psychotria_viridis
|
| gptkbp:affects |
euphoria
hallucinations spiritual experiences altered perception intense visual experiences |
| gptkbp:composed_of |
can be synthesized chemically
can be extracted from plants |
| gptkbp:cultural_significance |
featured in documentaries
subject of scientific studies discussed in literature used in indigenous cultures explored in modern spirituality |
| gptkbp:discovered_by |
Dr. Stephen Szara
|
| gptkbp:duration |
15 to 60 minutes
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
dimethyltryptamine (DMT)
|
| gptkbp:ingredients |
C12 H16 N2
|
| gptkbp:legal_issue |
varies by country
|
| gptkbp:manager |
oral
intravenous smoking |
| gptkbp:mass |
188.25 g/mol
|
| gptkbp:metabolism |
primarily in the liver
|
| gptkbp:occurs_in |
in the human body
in various plants |
| gptkbp:premiered_on |
seconds to minutes
|
| gptkbp:previous_name |
gptkb:N,_N-Dimethyltryptamine
|
| gptkbp:products |
gptkb:5-Me_O-DMT
gptkb:charity |
| gptkbp:replaced_by |
gptkb:1956
|
| gptkbp:research_areas |
gptkb:psychologist
neuroscience psychedelic therapy |
| gptkbp:side_effect |
anxiety
nausea confusion paranoia increased heart rate |
| gptkbp:type_of |
61-54-1
|
| gptkbp:used_in |
gptkb:Ayahuasca
shamanic rituals |